Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Revenue: Q2-FY25 revenue at Rs 10,263 mn, up 16.8% YoY and up 17.9% QoQ. H1-FY25 revenue at Rs 18,966 mn, up 22.1% YoY.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback